A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1

Những quyển sách tương tự

• A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
  Bằng: Park, Cheol-Kyu, et al.
  Được phát hành: (2019)
• Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
  Bằng: Xiaoying Zhang
  Được phát hành: (2021-06-01)
• Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
  Bằng: Park, Cheol Kyu, et al.
  Được phát hành: (2017)
• Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report
  Bằng: Li, Jie, et al.
  Được phát hành: (2020)
• Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
  Bằng: Park, Mi-Young, et al.
  Được phát hành: (2017)